Odel Soren

Odel Soren

Auto-generated profile, based on publicly available information

Odel Soren

Biological Sciences and Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, United Kingdom

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2016 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
HLHelena Lund-Palau
Helena Lund-Palau
ATAndrew R. Turnbull
Andrew R. Turnbull
ABAndrew Bush
Andrew Bush
EBEmmanuelle Bardin
Emmanuelle Bardin
LCLoren Cameron
Loren Cameron
JDJane C. Davies
Jane C. Davies
Pseudomonas aeruginosa is a remarkably versatile environmental bacterium with an extraordinary capacity to infect the cystic fibrosis (CF) lung. Infection with P. aeruginosa occurs early, and although eradication can be achieved following early detection, chronic infection occurs in over 60% of adults with CF. Chronic infection is associated with accelerated disease progression and increased mortality. Extensive research has revealed complex mechanisms by which P. aeruginosa adapts to and persists within the CF airway. Yet knowledge gaps remain, and prevention and treatment strategies are limited by the lack of sensitive detection methods and by a narrow armoury of antibiotics. Further developments in this field are urgently needed in order to improve morbidity and mortality in people with CF. Here, we summarize current knowledge of pathophysiological mechanisms underlying P. aeruginosa infection in CF. Established treatments are discussed, and an overview is offered of novel detection methods and therapeutic strategies in development.

15 June 2017 in FEMS Microbiology Letters
Verified
Journal Article
Open access
PDF file
WSWynne D. Smith
Wynne D. Smith
EBEmmanuelle Bardin
Emmanuelle Bardin
LCLoren Cameron
Loren Cameron
CEClaire L. Edmondson
Claire L. Edmondson
KFKatie V. Farrant
Katie V. Farrant
JDJane C. Davies
Jane C. Davies
Pseudomonas aeruginosa opportunistically infects the airways of patients with cystic fibrosis and causes significant morbidity and mortality. Initial infection can often be eradicated though requires prompt detection and adequate treatment. Intermittent and then chronic infection occurs in the majority of patients. Better detection of P. aeruginosa infection using biomarkers may enable more successful eradication before chronic infection is established. In chronic infection P. aeruginosa adapts to avoid immune clearance and resist antibiotics via efflux pumps, β-lactamase expression, reduced porins and switching to a biofilm lifestyle. The optimal treatment strategies for P. aeruginosa infection are still being established, and new antibiotic formulations such as liposomal amikacin, fosfomycin in combination with tobramycin and inhaled levofloxacin are being explored. Novel agents such as the alginate oligosaccharide OligoG, cysteamine, bacteriophage, nitric oxide, garlic oil and gallium may be useful as anti-pseudomonal strategies, and immunotherapy to prevent infection may have a role in the future. New treatments that target the primary defect in cystic fibrosis, recently licensed for use, have been associated with a fall in P. aeruginosa infection prevalence. Understanding the mechanisms for this could add further strategies for treating P. aeruginosa in future.

1 October 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
OSOdel Soren
Odel Soren
KBKaroline Sidelmann Brinch
Karoline Sidelmann Brinch
DPDipesh Patel
Dipesh Patel
YLYingjun Liu
Yingjun Liu
ALAlexander Liu
Alexander Liu
YHYanmin Hu
Yanmin Hu
The spread of antibiotic resistance among Gram-negative bacteria is a serious clinical threat, and infections with these organisms are a leading cause of mortality worldwide. Traditional novel drug development inevitably leads to the emergence of new resistant strains, rendering the new drugs ineffective. Therefore, reviving the therapeutic potentials of existing antibiotics represents an attractive novel strategy. Novicidin, a novel cationic antimicrobial peptide, is effective against Gram-negative bacteria. Here, we investigated novicidin as a possible antibiotic enhancer. The actions of novicidin in combination with rifampin, ceftriaxone, or ceftazidime were investigated against 94 antibiotic-resistant clinical Gram-negative isolates and 7 strains expressing New Delhi metallo-β-lactamase-1. Using the checkerboard method, novicidin combined with rifampin showed synergy with >70% of the strains, reducing the MICs significantly. The combination of novicidin with ceftriaxone or ceftazidime was synergistic against 89.7% of the ceftriaxone-resistant strains and 94.1% of the ceftazidime-resistant strains. Synergistic interactions were confirmed using time-kill studies with multiple strains. Furthermore, novicidin increased the postantibiotic effect when combined with rifampin or ceftriaxone. Membrane depolarization assays revealed that novicidin alters the cytoplasmic membrane potential of Gram-negative bacteria. In vitro toxicology tests showed novicidin to have low hemolytic activity and no detrimental effect on cell cultures. We demonstrated that novicidin strongly rejuvenates the therapeutic potencies of ceftriaxone or ceftazidime against resistant Gram-negative bacteria in vitro . In addition, novicidin boosted the activity of rifampin. This strategy can have major clinical implications in our fight against antibiotic-resistant bacterial infections.

17 September 2019 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
OSOdel Soren
Odel Soren
ARArdeshir Rineh
Ardeshir Rineh
DSDiogo G Silva
Diogo G Silva
YCYuming Cai
Yuming Cai
RHRobert P Howlin
Robert P Howlin
JWJeremy S Webb
Jeremy S Webb
The cephalosporin nitric oxide (NO)-donor prodrug DEA-C3D (‘DiEthylAmin-Cephalosporin-3′-Diazeniumdiolate’) has been shown to initiate the dispersal of biofilms formed by the Pseudomonas aeruginosa laboratory strain PAO1. In this study, we investigated whether DEA-C3D disperses biofilms formed by clinical cystic fibrosis (CF) isolates of P. aeruginosa and its effect in combination with two antipseudomonal antibiotics, tobramycin and colistin, in vitro. β-Lactamase-triggered release of NO from DEA-C3D was confirmed using a gas-phase chemiluminescence detector. MICs for P. aeruginosa clinical isolates were determined using the broth microdilution method. A crystal violet staining technique and confocal laser scanning microscopy were used to evaluate the effects of DEA-C3D on P. aeruginosa biofilms alone and in combination with tobramycin and colistin. DEA-C3D was confirmed to selectively release NO in response to contact with bacterial β-lactamase. Despite lacking direct, cephalosporin/β-lactam-based antibacterial activity, DEA-C3D was able to disperse biofilms formed by three P. aeruginosa clinical isolates. Confocal microscopy revealed that DEA-C3D in combination with tobramycin produces similar reductions in biofilm to DEA-C3D alone, whereas the combination with colistin causes near complete eradication of P. aeruginosa biofilms in vitro. DEA-C3D is effective in dispersing biofilms formed by multiple clinical isolates of P. aeruginosa and could hold promise as a new adjunctive therapy to patients with CF.

1 May 2017 in Nitric Oxide
Verified
Journal Article
Closed access
RARaymond Allan
Raymond Allan
MKMichael Kelso
Michael Kelso
ARArdeshir Rineh
Ardeshir Rineh
Nageshwar Rao YepuriNageshwar Rao Yepuri
Nageshwar Rao Yepuri
MFMartin Feelisch
Martin Feelisch
SFSaul N. Faust
Saul N. Faust

24 April 2020 in ACS Infectious Diseases
Verified
Journal Article
Open access
ARArdeshir Rineh
Ardeshir Rineh
OSOdel Soren
Odel Soren
TMTimothy McEwan
Timothy McEwan
VRVikashini Ravikumar
Vikashini Ravikumar
WPWee Han Poh
Wee Han Poh
MKMichael Kelso
Michael Kelso
The formation of biofilms provides a formidable defense for many bacteria against antibiotics and host immune responses. As a consequence, biofilms are thought to be the root cause of most chronic infections, including those occurring on medical indwelling devices, endocarditis, urinary tract infections, diabetic and burn wounds and bone and joint infections. In cystic fibrosis (CF), chronic Pseudomonas aeruginosa respiratory infections are the leading cause of morbidity and mortality in adults. Previous studies have shown that many bacteria can undergo a coordinated dispersal event in the presence of low concentrations of nitric oxide (NO), suggesting that NO could be used to trigger biofilm dispersal in chronic infections and enable clearance of the more vulnerable planktonic cells. In this proof-of-principle study, we describe efforts to create ‘all-in-one’ cephalosporin-based NO donor prodrugs (cephalosporin-3´-diazeniumdiolates, C3Ds) that show both direct beta-lactam mediated antibacterial activity and NO-induced antibiofilm effects. Twelve novel C3Ds were synthesized and screened against a panel of P. aeruginosa CF clinical isolates and other human pathogens. The most active compound, AMINOPIP2-ceftazidime 12, showed higher antibacterial potency than its parent cephalosporin and front-line antipseudomonal antibiotic ceftazidime, good stability against beta-lactamases, activity against ceftazidime-resistant P. aeruginosa in vitro biofilms and efficacy equivalent to ceftazidime in a murine P. aeruginosa respiratory infection model. The results support further evaluation of AMINOPIP2-ceftazidime 12 for P. aeruginosa lung infections in CF and broader study of ‘all-in-one’ C3Ds for other chronic infections.